Halozyme Therapeutics (HALO) Tops Q2 EPS by 47c; raises guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $2.28, $0.47 better than the analyst estimate of $1.81. Revenue for the quarter came in at $481 million versus the consensus estimate of $401.27 million.

GUIDANCE:

Halozyme Therapeutics sees FY2026 EPS of $8.65-$9.00, versus the consensus of $8.10. Halozyme Therapeutics sees FY2026 revenue of $1.835-1.910 billion, versus the consensus of $1.768 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• CoreWeave (CRWV) Reiterated at Neutral by DA Davidson Amid Rising Cost of Capital
• LiqTech International (LIQT) Reports In-Line Q2 EPS